QLS-111
/ Qlaris Bio
- LARVOL DELTA
Home
Next
Prev
1 to 17
Of
17
Go to page
1
August 30, 2025
QC-111-202: Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
(clinicaltrials.gov)
- P2 | N=36 | Recruiting | Sponsor: Qlaris Bio, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Glaucoma • Ophthalmology
March 26, 2025
Safety, tolerability and ocular hypotensive properties of QLS-111, a novel formulation of an ATP sensitive potassium channel opener, alone or in combination with approved ocular hypotensive drugs
(ARVO 2025)
- "These findings highlight the potential of QLS-111 as a strong and well-tolerated therapeutic option for better management of intraocular pressure in diseases like glaucoma. Clinical trials are currently underway to explore the benefits of QLS-111, either alone or in combination with latanoprost, in patients with glaucoma or elevated eye pressure."
Clinical • Combination therapy • Glaucoma • Ophthalmology
March 18, 2025
QC-111-202: Study of an Investigational Product, QLS-111, Provided As an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
(clinicaltrials.gov)
- P2 | N=36 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | N=60 ➔ 36
Enrollment change • Glaucoma • Ophthalmology
February 05, 2025
Qlaris Bio Announces Positive Topline Data From…Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
(Businesswire)
- P2 | N=36 | Apteryx (NCT06249152) | Sponsor: Qlaris Bio, Inc. | "The Phase II trials...successfully met all primary and secondary endpoints...The Apteryx study...QLS-111 0.015% dosed with latanoprost drove additive mean IOP reductions as compared to latanoprost monotherapy, achieving a 3.2 mmHg greater reduction for QLS-111 QPM dosing and 3.6 mmHg greater reduction for QLS-111 BID (twice daily) dosing."
P2 data • Glaucoma • Ophthalmology
February 05, 2025
Qlaris Bio Announces Positive Topline Data From…Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
(Businesswire)
- P2 | N=63 | Osprey (NCT06016972) | Sponsor: Qlaris Bio, Inc. | "The Phase II trials...successfully met all primary and secondary endpoints. Qlaris Bio will present a corporate update at the Glaucoma 360 New Horizons Forum 2025 on February 7th in San Francisco, CA. The Osprey study...demonstrated that the 0.015% concentration of QLS-111 dosed QPM (once daily in the evening) drove the greatest decrease in IOP, highlighted by mean reductions of 3.7 mmHg from mean diurnal baseline IOP of 23.0 mmHg."
P2 data • Glaucoma • Ophthalmology
January 23, 2025
QC-111-203: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
(clinicaltrials.gov)
- P2 | N=36 | Completed | Sponsor: Qlaris Bio, Inc. | Recruiting ➔ Completed
Trial completion • Cardiovascular • Glaucoma • Ophthalmology
January 23, 2025
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
(clinicaltrials.gov)
- P2 | N=63 | Completed | Sponsor: Qlaris Bio, Inc. | Active, not recruiting ➔ Completed
Trial completion • Cardiovascular • Glaucoma • Ophthalmology
January 17, 2025
Qlaris Phase 2 Study in NTG Patients
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | Trial completion date: Apr 2025 ➔ Oct 2025 | Trial primary completion date: Mar 2025 ➔ Oct 2025
Trial completion date • Trial primary completion date • Glaucoma • Ophthalmology
August 27, 2024
Qlaris Phase 2 Study in NTG Patients
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | N=120 ➔ 60
Enrollment change • Glaucoma • Ophthalmology
August 27, 2024
Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
(clinicaltrials.gov)
- P2 | N=60 | Active, not recruiting | Sponsor: Qlaris Bio, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Cardiovascular • Glaucoma • Ophthalmology
April 09, 2024
QC-111-203: Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
(clinicaltrials.gov)
- P2 | N=48 | Recruiting | Sponsor: Qlaris Bio, Inc. | Not yet recruiting ➔ Recruiting
Combination therapy • Enrollment open • Cardiovascular • Glaucoma • Ophthalmology
March 19, 2024
Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Qlaris Bio, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Glaucoma • Ophthalmology
February 16, 2024
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
(clinicaltrials.gov)
- P2 | N=48 | Not yet recruiting | Sponsor: Qlaris Bio, Inc.
Combination therapy • New P2 trial • Cardiovascular • Glaucoma • Ophthalmology
January 29, 2024
Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | N=120 ➔ 60 | Trial completion date: Dec 2024 ➔ Sep 2024
Enrollment change • Trial completion date • Cardiovascular • Glaucoma • Ophthalmology
November 15, 2023
Qlaris Phase 2 Study in NTG Patients
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Qlaris Bio, Inc. | Initiation date: Feb 2024 ➔ May 2024
Trial initiation date • Glaucoma • Ophthalmology
September 08, 2023
Qlaris Phase 2 Study in NTG Patients
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Qlaris Bio, Inc.
New P2 trial • Glaucoma • Ophthalmology
August 30, 2023
Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
(clinicaltrials.gov)
- P2 | N=120 | Not yet recruiting | Sponsor: Qlaris Bio, Inc.
New P2 trial • Cardiovascular • Glaucoma • Ophthalmology
1 to 17
Of
17
Go to page
1